The role of inflammation in cervical cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 377-399

  Deivendran, S ^a   Marzook, K Hezlin ^a   Pillai, M Radhakrishna ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; IFOSFAMIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; MITOMYCIN; PACLITAXEL; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; CEDIRANIB; CETUXIMAB; CHEMOKINE; GELATINASE B; HYDRALAZINE; INTERLEUKIN 12P35; INTERLEUKIN 12P40; PANITUMUMAB; PAZOPANIB; REACTIVE OXYGEN METABOLITE; UNINDEXED DRUG; VALPROIC ACID;

AFRICA; ARTICLE; ASIA; BRACHYTHERAPY; CANCER CELL LINE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHEMORADIOTHERAPY; COX 2 GENE; DISEASE ASSOCIATION; DNA POLYMORPHISM; EUROPE; GENE PRODUCT; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INOS GENE; MALIGNANT TRANSFORMATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PACIFIC ISLANDS; PAPILLOMAVIRUS INFECTION; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RADICAL HYSTERECTOMY; SIGNAL TRANSDUCTION; TUMOR INVASION; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER THERAPY; CELL INVASION; CELL SURVIVAL; CELL TRANSFORMATION; IL12A GENE; IL2B GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); VIRUS INFECTION; WART VIRUS;

EID: 84959221422     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_15     Document Type: Article

References (63)

1. Al-Tahhan MA, Etewa RL, el Behery MM (2011) A ssociation between circulating interleukin-1 beta (IL-1beta) levels and IL-1beta C-511T polymorphism with cervical cancer risk in Egyptian women. Mol Cell Biochem 353:159-165
2. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS (2005) E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 113:276-283
3. Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, Pinto LA (2011) Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine 53:282-285
4. Barbisan G Perez LO Contreras A Golijow CD 2012 TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33: 1549-1556
5. Basile JR, Zacny V, Munger K (2001) The cytokines tumor necrosis fac tor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 276:22522-22528
6. Bodily JM, Mehta KP, Laimins LA (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res 71:1187-1195
7. Chang YE, Laimins LA (2000) Microarray analysis identifies interferon-inducible genes and stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74:4174-4182
8. Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, Shi X, Qian N, Wang X, Wei Q, Shen H, Hu Z (2009) Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res 15:400-40 5
9. Chiantore MV, Vannucchi S, Accardi R, Tommasino M, Percario ZA, Vaccari G, Affabris E, Fiorucci G, Romeo G (2012) Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transform ed human keratinocytes by affecting p53 transactivating activity. PLoS One 7:e36909
10. Coleman MP, Quaresma M, Berrino F, Lutz JM, de Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hak ulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, Ga ES, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL (2008) Cancer survival in five continents: a worldwide pop ulation-based study (CONCORD). Lancet Oncol 9:730-756
11. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Se ssa C (2012) On behalf of the Esmo guidelines working group 2012. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23, vii27-vii32
12. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081
13. de Marco F, Bucaj E, Foppoli C, Fiorini A, Blarzino C , Filipi K, Giorgi A, Schinina ME, di Domenico F, Coccia R, Butterfield DA, Perluigi M (2012) Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues. PLoS One 7:e34366
14. Decarlo CA, Severini A, Edler L, Escott NG, Lambert PF, Ulanova M, Zehbe I (2010) IFNkappa, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. La b Invest 90:1482-1491
15. Degregori J, Johnson DG (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6:739-748
16. Ding B, Fu S, Wang M, Yue C, Wang W, Zhou D, Zhang Z, Han S (2012) Tumor necrosis factor alpha-308 G A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 22:213-219
17. D onovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK (2011) Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11:39-44
18. Du M, Fan X, Hong E, Chen JJ (2002) Interaction of oncogenic papillomavirus E6 proteins with fibulin-1. Biochem Biophys Res Commun 296:962-969
19. D uenas-Gonzalez A, Cetina L, Coronel J, Cervantes-Madrid D (2012) Emerging drugs for cervical cancer. Expert Opin Emerg Drugs 17:203-218
20. Duensing S, Munger K (2003) Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J Virol 77:12331-12335
21. Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S (2006) Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 25:2943-2949
22. Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, Hellstrom I, Hellstrom KE (2012) Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 127:412-419
23. Ferlay J, Parkin DM, Steliarova-Foucher E (2010a) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
24. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010b) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
25. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ (2002) The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 27 7:21730-21739
26. Filippova M, Parkhurst L, Duerksen-Hughes PJ (2004) The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 279 :25729-25744
27. Fitzgerald DW, Bezak K, Ocheretina O, Riviere C, Wright TC, Milne GL, Zhou XK, Du B, Subbaramaiah K, Byrt E, Goodwin ML, Rafii A, Dannenberg AJ (2012) The effect of HI V and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) 5:34-40
28. Gaiotti D, Chung J, Iglesias M, Nees M, Baker PD, Evans CH, Woodworth CD (2000) Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog 27:97-109
29. Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6-174G C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11-16
30. Garland SM, Bhatla N, Ngan HY (2012) Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev 21:1414-1422
31. Garnett TO, Duerksen-Hughes PJ (2006) Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 151:2321-2335
32. Garnett TO, Filippova M, Duerksen-Hughes PJ (2006) Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis . Cell Death Differ 13:1915-1926
33. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65:4673-4682
34. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375-1382
35. Huibregtse JM, Scheffner M, Howley PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10:4129-4135
36. Kang S, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP (2007) Interleukin-1 beta-511 polymorphism and risk of cervical cancer. J Korean Med Sci 22:110-113
37. Karin M ( 2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
38. Kemp TJ, Hildesheim A, Garcia-Pineres A, Williams MC, Shearer GM, Rodriguez AC, Schiffman M, Burk R, Freer E, Bonilla J, Herrero R, Pinto LA (2010) Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 19:1954-1959
39. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M (2004) Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18:300-310
40. L ammens T, Li J, Leone G, de Veylder L (2009) Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol 19:111-118
41. Lee TS, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS (2007) Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci 1095:134-142
42. Lee S, Kim JH, Kim H, Kang JW, Kim SH, Yang Y, Kim J, Park J, Park S, Hong J, Yoon DY (2011) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132:410-420
43. Ma S, Tang J, Feng J, Xu Y, Yu X, Deng Q, Lu Y (2008) Induction of p21 by p65 in p53 null cells treated with Doxorubicin. Biochim Biophys Acta 1783:935-940
44. McCormack SJ, Brazinski SE, Moore JL, Werness BA, Goldstein DJ (1997) Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 15:265-274
45. Okamoto T, Sanda T, Asamitsu K (2007) NF-kappa B signaling and carcinogenesis. Curr Pharm Des 13:447-462
46. Pandey S, Mittal B, Srivastava M, Singh S, Srivastava K, Lal P, Mittal RD (2011) Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene po lymorphisms in cervical cancer susceptibility. Mol Biol Rep 38:4715-4721
47. Park JS Kim EJ Kwon HJ Hwang ES Namkoong SE Um SJ 2000 Inactivation of interferon regulatory factor-1 tumor suppre ssor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis J Biol Chem 275:6764-6769
48. Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18:5061-5072
49. Poljak M (2012) Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clin Microbiol Infect 18(Suppl 5):64-69
50. Reiser J, Hurst J, Voges M, Krauss P, Munch P, Iftner T, Stubenrauch F (2011) High-risk human papillomaviruses repress constitutive kappa int erferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 85:11372-11380
51. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, Bachmann A, Ri tter TM, Dondog B, Ly R, Bosch FX, Zawatzky R, Rosl F (2009) Epigenetic silencing of interferonkappa in human papillomavirus type 16-positive cells. Cancer Res 69:8718-8725
52. Ronco LV, Karpova AY, Vidal M, Howley PM (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12:2061-2072
53. Sankaranarayanan (2011) Cancer survival in Africa, Asia, the Caribbean and Central America. Introduction. IARC Sci Publ, pp 1-5
54. Sasagawa T, Takagi H, Makinoda S (2012) Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 18:807-815
55. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890-907
56. Shekari M, Kordi-Tamandani DM, Malekzadeh K, Sobti RC, Karimi S, Suri V (2012) Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cerv ical carcinoma. Am J Clin Oncol 35:514-519
57. Singh H, Sachan R, Goel H, Mittal B (2008) Genetic variants of interleukin-1RN and interleukin-1beta genes and risk of cervical cancer. BJOG 115:633-638
58. Singh H, Jain M, Sachan R, Mittal B (2009) Association of TNFA (-308G A) and IL-10 (-819C T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer 19:1190-1194
59. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, Banchereau J, Fridman WH, Wijdenes J, Lebecque S, Sautes-Fridman C (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59:3698-3704
60. Wang Q, Zhang C, Walayat S, Chen HW, Wang Y (2011) Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol 158:330-333
61. Wang N, Yin D, Zhang S, Wei H, Wang S, Zhang Y, Lu Y, Dai S, Li W, Zh ang Q (2012) TNFalpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population. PLoS One 7:e45246
62. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550-3560
63. Zhou F, Leggatt GR, Frazer IH (2011) Human papilloma virus 16 E7 protein inhibits interferongamma-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS J 278:955-963